Eli Lilly and Company (NYSE:LLY) Trading Up 1.9% Following Better-Than-Expected Earnings

Key Points

• Eli Lilly beat quarterly expectations: Earnings per share came in at $8.38 versus the $6.16 consensus, while revenue rose 47.7% year over year to $22.97 billion, driven by strong Mounjaro and Zepbound demand.
• Management raised its 2026 outlook to $85 billion–$87 billion in revenue and $35.50–$36.50 in EPS, helping lift shares 1.9% in mid-day trading.
• Growth remains concentrated in obesity and diabetes treatments, creating risks from valuation, manufacturing capacity, competition and pricing pressure. Lilly also declared a quarterly dividend of $1.73 per share, representing a 0.6% annualized yield.

Eli Lilly and Company (NYSE:LLY - Get Free Report) shares traded up 1.9% during mid-day trading on Thursday following a stronger than expected earnings report. The company traded as high as $1,230.88 and last traded at $1,191.8720. 3,041,356 shares traded hands during mid-day trading, a decline of 3% from the average session volume of 3,137,871 shares. The stock had previously closed at $1,169.86.

The company reported $8.38 earnings per share for the quarter, topping analysts' consensus estimates of $6.16 by $2.22. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.69 billion. During the same period in the prior year, the firm earned $6.31 earnings per share. The business's quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q2 results exceeded expectations. Revenue rose 48% year over year to approximately $23.0 billion, while non-GAAP EPS reached $8.38 versus the $6.16 consensus estimate. The results were driven primarily by volume growth for Mounjaro and Zepbound. Eli Lilly easily tops quarterly estimates and raises outlook
• Positive Sentiment: Management raised its 2026 outlook again. Lilly now expects full-year revenue of $85 billion to $87 billion, up from $82 billion to $85 billion previously, and provided EPS guidance of $35.50 to $36.50. The higher forecast reflects sustained demand for diabetes and obesity treatments. Eli Lilly raises annual revenue forecast
• Positive Sentiment: The weight-loss franchise continues to expand rapidly. Mounjaro sales increased 91%, while Mounjaro and Zepbound together generated nearly $15 billion in quarterly revenue and approximately two-thirds of total sales. Foundayo adoption is also gaining traction, with broader Medicare access supporting the addressable market. LLY Q2 earnings call raises outlook as Foundayo gains traction
• Positive Sentiment: Pipeline and distribution developments add to the growth story. Lilly is advancing retatrutide toward a potential 2027 filing and expanding early access for certain patients. A new CVS weight-management partnership could improve GLP-1 distribution and patient access. Cantor Fitzgerald also raised its LLY price target to $1,410 and maintained an Overweight rating. Eli Lilly raises 2026 outlook again
• Neutral Sentiment: Competitive sentiment has improved for Lilly. Novo Nordisk also beat estimates and raised guidance, but investors reacted more favorably to Lilly’s results, reinforcing perceptions that Lilly is widening its lead in the obesity-drug market. The divide between Eli Lilly and Novo Nordisk is widening
• Negative Sentiment: Valuation and concentration remain risks. LLY trades at a high earnings multiple after a substantial rally, and much of its growth is concentrated in GLP-1 products. Manufacturing capacity, future competition, pricing pressure and the need to sustain exceptional demand could limit additional upside.
• Neutral Sentiment: Amazon’s Medicare initiative may broaden access but increase competitive and pricing pressure. The program will offer Wegovy, Zepbound and Foundayo through Amazon Pharmacy for eligible patients, potentially supporting demand while intensifying price-based competition. Amazon is bringing the weight-loss drug race to Medicare

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on LLY. Barclays upped their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a report on Monday, May 4th. Jefferies Financial Group boosted their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a "buy" rating in a research report on Tuesday, June 9th. Royal Bank Of Canada upped their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a report on Wednesday, July 8th. Morgan Stanley restated an "overweight" rating and set a $1,419.00 target price on shares of Eli Lilly and Company in a report on Thursday. Finally, Citigroup raised their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a "buy" rating in a research report on Wednesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $1,293.71.

Institutional Trading of Eli Lilly and Company

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock valued at $88,087,193,000 after acquiring an additional 1,006,885 shares in the last quarter. State Street Corp increased its position in shares of Eli Lilly and Company by 1.8% in the 4th quarter. State Street Corp now owns 35,361,916 shares of the company's stock worth $38,002,744,000 after purchasing an additional 635,358 shares during the last quarter. Morgan Stanley raised its stake in Eli Lilly and Company by 2.7% during the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company's stock valued at $16,757,510,000 after buying an additional 407,166 shares in the last quarter. Capital World Investors raised its position in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company's stock valued at $16,154,619,000 after acquiring an additional 61,851 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Eli Lilly and Company by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company's stock worth $16,024,022,000 after purchasing an additional 1,432,069 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 1.9%

The stock has a market cap of $1.12 trillion, a price-to-earnings ratio of 42.34, a price-to-earnings-growth ratio of 1.39 and a beta of 0.51. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm's 50 day moving average is $1,156.45 and its two-hundred day moving average is $1,045.49.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source